Hereditary Hemorrhagic Telangiectasia (HHT) Treatment Program, a Center of Excellence at UCLA, is a multidisciplinary practice which facilitates the comprehensive coordination of care necessary for treating patients with HHT.
Learn more about our program >
Contact Us for an Appointment
(310) 481-7545 Phone
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder, affecting approximately 1 in 5000 persons. It is an "equal opportunity disorder"; all ethnicities and both genders are similarly affected.
Click here for the newest HHT clinical Guidelines >
Specific Complications
Nosebleeds
Pulmonary AVMs
Cerebral AVMs
Gastrointestinal bleeding
Hepatitis AVMs
Most children with HHT have normal, healthy childhoods, with or without nosebleeds. Pulmonary AVMs may develop before puberty, but complications in asymptomatic children are extremely rare. However, cerebral AVMs, which are generally present at birth, can bleed in childhood.
